NCT00003214View on ClinicalTrials.gov

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 31, 1996

Primary Completion Date

April 30, 2000

Study Completion Date

April 30, 2000

Conditions
Ovarian Cancer
Interventions
DRUG

carboplatin

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

in vitro sensitivity-directed chemotherapy

DRUG

paclitaxel

Trial Locations (10)

4031

Frauenspital, Basel, Basel

4500

Burgerspital, Solothurn, Solothurn

5001

Kantonspital Aarau, Aarau

8063

City Hospital Triemli, Zurich

CH 4051

Office of Walter Weber-Stadelman, Basel

CH-4031

University Hospital, Basel

CH-3010

Inselspital, Bern, Bern

CH-1211

Hopital Cantonal Universitaire de Geneva, Geneva

CH-6900

Istituto Oncologico della Svizzera Italiana, Lugano

CH-8008

Klinik Hirslanden, Zurich

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT00003214 - Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer | Biotech Hunter | Biotech Hunter